Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.64 |
| ▸ | TTK | P33981 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | LOX | P28300 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697031 | 0.84 | CA2 (0.62) | CA2STAT3CA1CA9CA7 | |
| SCHEMBL4959359 | 0.84 | SMN1; SMN2 (0.63) | CA2HDAC8HDAC6LOXAKR1C3 | |
| SCHEMBL7454308 | 0.84 | HDAC8 (0.58) | CA2HDAC8HDAC6LOXAKR1C3 | |
| SCHEMBL7119077 | 0.84 | HDAC6 (0.60) | CA2HDAC8HDAC6STAT3CA1 | |
| SCHEMBL12926128 | 0.83 | HDAC8 (0.56) | CA2HDAC8HDAC6LOXAKR1C3 | |
| SCHEMBL12060827 | 0.83 | LMNA (0.63) | HDAC8HDAC6LOXAKR1C3MEN1 | |
| SCHEMBL27585128 | 0.83 | CA2 (0.56) | CA2STAT3CA1CA9CA7 | |
| Hydrochloric Acid SCHEMBL8815102 | 0.81 | CA2 (0.51) | CA2STAT3CA1CA9CA7 | |
| SCHEMBL3347957 | 0.80 | CA2 (0.63) | CA2CA1CA9CA7KMT2A | |
| SCHEMBL14548240 | 0.80 | HDAC8 (0.53) | CA2HDAC8HDAC6LOXAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102036953-B | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| CN-102036953-A | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |